Anti-obesity medications including GLP-1 RAs show potential benefits for rheumatic disease patients through weight reduction and immunomodulatory effects, though rheumatology-specific evidence is limited.
Double benefit for jointsGLP-1 drugs could help rheumatic disease patients two ways: reducing weight (less joint stress) AND suppressing inflammation (less disease activity)
What the researchers found
GLP-1 RAs for rheumatic diseases: weight reduction + immunomodulation could improve disease activity, joint outcomes, and drug effectiveness in RA, PsA, OA, and gout.
Why it matters
Most rheumatic disease patients are overweight, worsening their condition. GLP-1 drugs could treat both obesity and the underlying inflammatory disease.
How the study worked
Review of anti-obesity medication potential in rheumatic diseases, focusing on GLP-1 RAs.
What this study cannot tell us
Limited rheumatology-specific evidence. Most data extrapolated from metabolic trials.
How to read the evidence
Review with extrapolated evidence.
When this study was published
Published in 2025.
The bigger picture
The overlap between metabolic and rheumatic inflammation positions GLP-1 drugs as potential disease-modifying agents for rheumatology.
Questions still open
- Should GLP-1 drugs be trialed specifically for RA?
- Could weight loss alone explain the rheumatologic benefits?
- Would combining GLP-1 drugs with DMARDs improve RA outcomes?
Common questions
Can GLP-1 drugs help arthritis?
Should I ask my rheumatologist about GLP-1 drugs?
Read the original research
Antiobesity medications in rheumatology. Quo vadis?
Annals of the rheumatic diseases, 85(3), 412-416
Citation
Kyriazi, Niki; Vassilakis, Konstantinos D; Bakiri, Amalia; Iliopoulos, Alexios; Fragoulis, George E. (2026). Antiobesity medications in rheumatology. Quo vadis?. Annals of the rheumatic diseases, 85(3), 412-416. https://doi.org/10.1016/j.ard.2025.08.013